LYBALVI (OLANZAPINE AND SAMIDORPHAN) IN THE MANAGEMENT OF SCHIZOAFFECTIVE DISORDER IN AN ADULT WITH PRADER-WILLI SYNDROME

Prader-Willi syndrome (PWS) is a neurodevelopmental genomic imprinting disorder characterized by obesity, behavioral issues, mental illness, and self-injury. Managing psychiatric symptoms in PWS is a clinical challenge because of significant weight gain associated with antipsychotic medications in an already obese patient population. We report a case of a patient with Prader Willi syndrome and schizoaffective disorder (depressive type) treated with Lybalvi (olanzapine and samidorphan) and followed up after a month with a gradual increase in the dose of olanzapine, leading to the resolution of hallucinations without a significant increase in weight. This case highlights the potential use of Lybalvi for patients with psychiatric illnesses who are overweight, obese, or vulnerable to the hazardous effects of weight gain, including Prader-Willi syndrome. Further research into the use of Lybalvi in vulnerable populations is required to strengthen its association and benefits.